Wahi a kahi noiʻi hou e Persistence Market Research, ke manaʻo nei ka mākeke olakino olakino e ʻike i ka ulu kiʻekiʻe ma kahi CAGR ma kahi o 14.8% a hiki i kahi kumukūʻai o US $ 76.5 Bn e 2031.
Hoʻokumu ʻia ka marijuana lāʻau mai ka lāʻau Cannabis sativa. ʻO nā pūhui ikaika nui ʻekolu o ka mea kanu he tetrahydrocannabinol, cannabidiol, a me cannabinol. He mau noi like ʻole ka lāʻau lapaʻau i ka mālama olakino a me ka lapaʻau lapaʻau, me ka mālama ʻana a i ʻole ka mālama ʻana i ka ʻeha, ka mālama ʻana i ka nausea, nā ʻiʻo spasms, ka mālama ʻana i ka hopohopo, ka sclerosis lehulehu, ka haʻahaʻa haʻahaʻa, nā pilikia hiamoe, a me nā mea he nui.
ʻO nā kumu ʻē aʻe e koi ai i ka lāʻau lapaʻau e pili ana i ka hiki ke mālama a mālama i ka insomnia a me ka epilepsy. Wahi a ka poʻe loea mālama ola kino, he koho kūpono ka lāʻau lapaʻau no ka hoʻoponopono ʻana i nā pilikia pili i ka hiamoe no ka mea e hoʻihoʻi ia i ke kaʻina hiamoe kūlohelohe o ke kanaka e loli ana ma muli o ke ʻano o kēia mau lā.
ʻIke ʻia ʻo marijuana lāʻau no kāna mau waiwai anti-inflammatory ikaika. Hiki iā ia ke mālama i ka ʻāʻī mai ka maʻi arthritis a me nā loli degenerative i loko o ka lumbar, cervical or thoracic spine. Nui nā poʻe maʻi e hoʻohana i ka marijuana e mālama i ko lākou ʻeha i hana ʻia ma muli o ka mumū.
Hoʻokumu ʻia nā hui lāʻau lapaʻau i ka loaʻa ʻana o nā ʻae mai nā luna aupuni ʻē aʻe no ka hoʻohana ʻana i ka lāʻau lapaʻau no nā kumu lapaʻau.
• I Kepakemapa 2019, ua ʻae ʻia ʻo GW Pharmaceuticals mai ʻEulopa i ke Komisina no EPIDYOLEX® (cannabidiol) no ka mālama ʻana i ka hopu ʻana i nā mea maʻi me ʻelua mau ʻano koʻikoʻi o ka wā kamaliʻi.
• I ʻOkakopa 2021, ua hoʻolaha ʻo Canopy Growth Corporation i kahi hoʻolālā e loaʻa iā Wana Entity, ʻo ia ka inoa o ka cannabis edibles kaulana ma ʻAmelika ʻĀkau.
• Ma ʻAukake 2020, hoʻolaha ʻo MedReleaf Corp. a me BioPharma Services Inc. i kā lākou ʻaelike e hana i ka noiʻi lapaʻau no ka cannabis a me nā huahana i loaʻa mai i ka cannabis.
Nā Takeaways Key mai ka Mākeke Study
• Hoʻohana nui ʻia ke ʻano extract o ka marijuana ma nā ʻano hana like ʻole i ka māla lapaʻau e like me nā pua maloʻo.
• Ua hauʻoli ka ʻāpana hoʻokele ʻeha i ka māhele mākeke kiʻekiʻe o 48.8%, e hōʻike ana i ke koi kiʻekiʻe no ka lāʻau lapaʻau i nā kaʻina hana hoʻomalu ʻeha.
• 77.6% ka māhele o ka mākeke ma ka māhele o ke kahawai hoʻolaha e mālama ʻia e nā hale kūʻai kūʻai, no ka mea, ua hoʻoponopono ʻia ka mākeke e nā luna aupuni.
• Hoʻomaka ka mākeke ʻAmelika ʻĀkau e ulu 5X e 2031.
"ʻO ka hoʻonui nui ʻana o ka ʻeha maʻi a me ka epilepsy a me ka legalization o ka lāʻau lapaʻau i nā ʻāina e ulu nei nā kumu nui e koi ai," wahi a kahi mea noiʻi ʻo Persistence Market Research.
ʻO wai ka Lanakila?
Ke hana mau nei nā mea hana lāʻau lapaʻau lāʻau i ka hoʻonui ʻana i kā lākou huahana portfolios a me ka hele ʻana o ka mākeke ma o nā hoʻolālā koʻikoʻi e like me ka ʻae ʻana o ka huahana a me ka hāʻawi ʻana a me nā ʻaelike hui.
• Ua loaʻa iā GW Pharmaceuticals ka ʻae ʻia mai Australian Therapeutic Goods Administration (TGA) no EPIDYOLEX® (cannabidiol) no ka maʻi epilepsy (2020). Ua ʻae ka FDA i ka hopena waha ʻo EPIDIOLEX® (cannabidiol) no ka mālama ʻana i nā maʻi e pili ana i ka paʻakikī o ka tuberous sclerosis.
• Ua pūlima ʻo Tilray i kahi ʻaelike hoʻolaha me nā mea hoʻolaha ʻākau nui no nā kūʻai cannabis hoʻohana kanaka makua ma Kanada.
